This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Pediatrics, Other  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Gastroenterology  • Gastrointestinal Diseases  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;302(11):1162.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drugs that block tumor necrosis factor (TNF) increase the risk of lymphomas and other cancers in pediatric patients receiving the drugs for inflammatory conditions such as juvenile rheumatoid arthritis or Crohn disease, according to an analysis by the US Food and Drug Administration (FDA).

The FDA has identified 48 cases of malignancies, including 11 resulting in death, in pediatric patients taking infliximab, etanercept, or adalimumab, usually in combination with other immunosuppressive therapies. The TNF blockers certolizumab and golimumab, approved more recently than the other 3 drugs, were not included in the analysis because they were not widely used during the period reviewed, the agency said. Almost half the cases involved lymphomas; leukemia, melanoma, and solid organ cancers were also seen. The FDA is requiring all drugs in this class to carry a boxed warning that they pose an increased risk of cancer in children.

Additionally, the agency . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?